Organon & Co.

Day range

—

Open

—

Prev close

$13.85

Volume

318

Market cap

$3.64B

Shares out

262.62M

P/E

17.08

P/S

0.60

P/B

3.05

P/FCF

5.39

ROE

17.8%

ROA

1.6%

Debt/Equity

7.17

Div yield

0.55%

As of Nov 9, 2026

• Investor presentationOct 30, 2026

  To continue this practice, the Company is furnishing certain supplemental non-GAAP metrics for the quarter ended September 30, 2026 that are included in Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

• Merger agreementJul 23, 2026

  Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "Merger Agreement"), dated April 26, 2026, by and among the Company, Sun Pharmaceutical Holdings USA, Inc. ("Sun Pharma USA"), and Sun Pharma America, Inc., a wholly owned subsidiary of Sun Pharma USA ("Merger Sub") and, solely for certain specified provisions, Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc. and Sun Pharma (Netherlands) B.V., pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Sun Pharma USA (the "Merger").

• Material litigationJul 17, 2026

  On July 6, 2026, a complaint was filed in connection with the Merger in the Superior Court of New Jersey, County of Mercer Chancery Division, against the Company, the current members of the board of directors (the "Board") of the Company, Sun Pharma USA and Merger Sub. The Complaint alleges, among other things, that certain disclosures in the Definitive Proxy Statement filed by the Company in connection with the Merger were materially incomplete and misleading. The Complaint further alleges violations of the New Jersey Uniform Securities Law, N.J. Stat. § 49:3-71, and, under New Jersey common law, negligent misrepresentation and concealment, general negligence, and civil conspiracy.

• Equity compensation grantJun 11, 2026

  The stockholders of Organon & Co. approved an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan... The Amended and Restated 2021 ISP increases the number of shares of the Company's common stock available for issuance thereunder by 8,000,000 shares.

• Executive officer appointmentApr 27, 2026

  As previously disclosed in a Current Report on Form 8-K filed by the Company on October 27, 2025, on October 26, 2025, Carrie S. Cox was appointed Executive Chair for an interim period. On April 26, 2026, Ms. Cox was appointed to serve as Executive Chair on a non-interim basis.

Days to cover

8.6

Short interest

18.82M

Avg volume

2.18M

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
  neutralZacks Investment Research· Oct 26, 2026
• Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
  neutralZacks Investment Research· Oct 14, 2026
• Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
  neutralZacks Investment Research· Oct 2, 2026
• BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
  negativeGlobeNewswire Inc.· Jun 22, 2026
• Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders
  negativeGlobeNewswire Inc.· Jun 16, 2026